Abstract:Background: In a proportion of adults with steroid-resistant nephrotic syndrome (SANS), intravenous cyclophosphamide therapy fails. Tacrolimus may be a promising alternative to cyclophosphamide for such patients. Study Design: Prospective observational study. Setting & Participants: 19 adults with SRNS (6 with minimal change nephropathy, 8 with focal segmental glomerulosclerosis [FSGS], and 5 with mesangioproliferative glomerulonephritis) that did not respond to intravenous cyclophosphamide therapy were studied from January 2003 to September 2006. Oral tacrolimus was administered (target trough levels, 5 to 10 ng/mL) for 24 weeks, then reduced doses were given (target trough level, 3 to 6 ng/mL) for another 24 weeks. Factors: Histopathologic types: minimal change nephropathy (n = 6), FSGS (n = 8), and mesangioproliferative glomerulonephritis (n = 5). Outcomes: Measurements: outcome variables included complete remission (decrease in daily proteinuria to protein <= 0.3 g/d), partial remission (decrease in daily proteinuria to protein < 3.5 g/d but > 0.3 g/d), relapse (increase in daily proteinuria to protein >= 3.5 g/d in patients who had partial or complete remission), change in kidney function, and tacrolimus dosing and serum levels. Results: 17 patients completed at least 24 weeks of tacrolimus therapy. Complete remission was achieved in 11 patients (64.7%), and partial remission was achieved in 3 (17.6%). Complete or partial remission was achieved in 5 of 5 patients with minimal change nephropathy, 4 of 7 patients with FSGS, and 5 of 5 patients with mesangioproliferative glomerulonephritis. Primary resistance to tacrolimus was seen in 3 patients (17.6%), all with FSGS. Mean times to achieve partial and complete remission were 5.6 +/- 1.4 and 8.0 +/- 5.1 weeks, respectively. In patients who achieved complete or partial remission, 35.7% experienced relapse during follow-up (mean, 37.6 +/- 13.4 months). Two patients had doubling of serum creatinine levels, both with FSGS. Limitations: Observational study. Conclusions: Tacrolimus rapidly and effectively induced remission of SRNS in Chinese adults with disease refractory to treatment with intravenous cyclophosphamide. Treatment may be less effective in patients with FSGS. Am J Kidney Dis 54:51-58. (c) 2009 by the National Kidney Foundation, Inc.

Treatment of Idiopathic Orbital Myositis with Frequent Relapses: First Case with Tacrolimus and Review of Literature

Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study

Tacrolimus Combined with Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled Trial

Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases

Early Initiation of Tacrolimus or Cyclophosphamide Therapy for Idiopathic Membranous Nephropathy with Severe Proteinuria.

Effectiveness of Tacrolimus in a Case of Immune Checkpoint Inhibitor-Induced Hepatotoxicity That Was Refractory to Steroids and Mycophenolate Mofetil

Tacrolimus in the Treatment of Ocular Diseases

Successful use of tacrolimus for treatment‐refractory neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia syndrome: A case series

Therapy of Tacrolimus Combined with Corticosteroids in Idiopathic Membranous Nephropathy

The Efficacy and Safety of Tacrolimus Monotherapy in Adult-Onset Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy

Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.

Mycophenolate mofetil for ocular inflammation

Clinical and Magnetic Resonance Imaging Features in Idiopathic Orbital Myositis:5 Cases Report

Magnetic Resonance Imaging of Idiopathic Orbital Myositis

Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids.

Remission and Relapses of Myasthenia Gravis on Long-Term Tacrolimus: a Retrospective Cross-Sectional Study of a Chinese Cohort

Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis

Tacrolimus Combined with Corticosteroids Improved the Outcome of CIDP Patients with Autoantibodies Against Paranodal Proteins

Outcomes of Tacrolimus Therapy in Adults with Refractory Membranous Nephrotic Syndrome: a Prospective, Multicenter Clinical Trial.

Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis:a retrospective analysis

Effect of Prolonged Tacrolimus Treatment in Idiopathic Membranous Nephropathy with Nephrotic Syndrome